STAT+: In China, a flood of controversial clinical trials slows to a trickle
· statnews.com · popularity 32/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at statnews.com →
Summary
Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.
Found in: STAT News. Rating basis: single outlet; outlet tier 4; 1 feeds; feed position 9.